class="blog wp-embed-responsive wp-theme-foxiz wp-child-theme-foxiz-child supp-body td-standard-pack personalized-all menu-ani-1 hover-ani-1 btn-ani-1 btn-transform-1 is-rm-1 lmeta-dot loader-1 dark-sw-1 mtax-1 is-hd-5 is-backtop none-m-backtop is-mstick is-smart-sticky"
HORMONE-SENSITIVE CONDITIONS: Contraindicated in oestrogen receptor-positive (ER+) breast cancer, endometrial cancer, uterine fibroids, endometriosis — oestrogenic activity may stimulate tumour growth. Thyroid: may interfere with thyroid hormone synthesis — caution in hypothyroidism. Drug interaction: tamoxifen (may antagonise). Fertility: high doses may affect menstrual cycle. Male fertility: high doses may reduce testosterone.
Soy isoflavone with oestrogenic activity (phytoestrogen) — binds oestrogen receptors ERα and ERβ with preference for ERβ. Metabolised by gut bacteria to equol (more potent oestrogenic metabolite) in approximately 30-50% of people. Used for menopausal symptoms, bone health, and cardiovascular risk.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly unsafe | — |
| Pregnancy | Possibly unsafe | — |
| Elderly | Possibly unsafe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)